795 related articles for article (PubMed ID: 28931759)
21. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
22. Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4
Gallotta M; Assi H; Degagné É; Kannan SK; Coffman RL; Guiducci C
Cancer Res; 2018 Sep; 78(17):4943-4956. PubMed ID: 29945961
[TBL] [Abstract][Full Text] [Related]
23. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.
Hosoya T; Sato-Kaneko F; Ahmadi A; Yao S; Lao F; Kitaura K; Matsutani T; Carson DA; Hayashi T
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6836-E6844. PubMed ID: 29967183
[TBL] [Abstract][Full Text] [Related]
24. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
Huang LL; Shi YK
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852
[TBL] [Abstract][Full Text] [Related]
25. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
26. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
[TBL] [Abstract][Full Text] [Related]
27. Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade.
Tachinami H; Nishii N; Xia Y; Kashima Y; Ohno T; Nagai S; Li L; Lau W; Tomihara K; Noguchi M; Azuma M
Oral Oncol; 2019 Apr; 91():21-28. PubMed ID: 30926058
[TBL] [Abstract][Full Text] [Related]
28. Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
[TBL] [Abstract][Full Text] [Related]
29. Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy.
Kim SY; Kim S; Kim JE; Lee SN; Shin IW; Shin HS; Jin SM; Noh YW; Kang YJ; Kim YS; Kang TH; Park YM; Lim YT
ACS Nano; 2019 Nov; 13(11):12671-12686. PubMed ID: 31589013
[TBL] [Abstract][Full Text] [Related]
30. The 5-Ws of immunotherapy in head and neck cancer.
Botticelli A; Mezi S; Pomati G; Cerbelli B; Di Rocco C; Amirhassankhani S; Sirgiovanni G; Occhipinti M; Napoli V; Emiliani A; Mazzuca F; Tomao S; Nuti M; Marchetti P
Crit Rev Oncol Hematol; 2020 Sep; 153():103041. PubMed ID: 32629362
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive T-cell immunophenotyping and next-generation sequencing of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas.
Poropatich K; Fontanarosa J; Swaminathan S; Dittmann D; Chen S; Samant S; Zhang B
J Pathol; 2017 Nov; 243(3):354-365. PubMed ID: 28771750
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma.
Baird JR; Bell RB; Troesch V; Friedman D; Bambina S; Kramer G; Blair TC; Medler T; Wu Y; Sun Z; de Gruijl TD; van de Ven R; Leidner RS; Crittenden MR; Gough MJ
Cancer Res; 2018 Nov; 78(21):6308-6319. PubMed ID: 30224374
[TBL] [Abstract][Full Text] [Related]
33. NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models.
Gruijs M; Ganzevles SH; Stigter-van Walsum M; van der Mast R; van Ostaijen-Ten Dam MM; Tuk CW; Schilham MW; Leemans CR; Brakenhoff RH; van Egmond M; van de Ven R; Bakema JE
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681717
[TBL] [Abstract][Full Text] [Related]
34. Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model.
Gadkaree SK; Fu J; Sen R; Korrer MJ; Allen C; Kim YJ
Head Neck; 2017 Jun; 39(6):1086-1094. PubMed ID: 28323387
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
Mei Z; Huang J; Qiao B; Lam AK
Int J Oral Sci; 2020 May; 12(1):16. PubMed ID: 32461587
[TBL] [Abstract][Full Text] [Related]
36. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
37. Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity.
Moreira D; Sampath S; Won H; White SV; Su YL; Alcantara M; Wang C; Lee P; Maghami E; Massarelli E; Kortylewski M
J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33232304
[TBL] [Abstract][Full Text] [Related]
38. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.
Yu GT; Bu LL; Huang CF; Zhang WF; Chen WJ; Gutkind JS; Kulkarni AB; Sun ZJ
Oncotarget; 2015 Dec; 6(39):42067-80. PubMed ID: 26573233
[TBL] [Abstract][Full Text] [Related]
39. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]